Brain Swelling from Alzheimer's Drugs May Signal Treatment Success, New Research Suggests
Key Insights
Houston Methodist researchers found that brain regions experiencing ARIA-E (search) swelling from Alzheimer's drugs like lecanemab and donanemab showed significantly greater amyloid plaque clearance compared to non-swollen areas.
The study analyzed PET scans from patients with moderate to severe brain swelling and found that 80% showed more substantial amyloid clearing in swollen regions, suggesting ARIA-E (search) may indicate strong local treatment activity.
These findings could reframe ARIA-E (search) from being viewed solely as an adverse side effect to a potential biomarker of therapeutic efficacy in amyloid-targeting treatments.
A side effect that has long concerned doctors treating Alzheimer's patients with the newest generation of drugs may actually signal that the treatment is working effectively, according to groundbreaking research from Houston Methodist Research Institute.
The study, published in the American Journal of Neuroradiology, examined patients who developed ARIA-E (search) (amyloid-related imaging abnormality with edema) - brain swelling that typically prompts physicians to pause or slow treatment with drugs like lecanemab and donanemab. Researchers found that brain regions experiencing this swelling showed significantly greater clearance of toxic amyloid plaques compared to areas that remained unaffected.
Swelling Correlates with Enhanced Amyloid Clearance
Led by Joseph Masdeu, M.D., Ph.D., director of the Nantz National Alzheimer Center and Neuroimaging, the research team analyzed PET scans from patients before and after ARIA-E (search) episodes had resolved. In four of five patients studied, areas that experienced moderate to severe swelling demonstrated substantially larger decreases in amyloid signal compared to regions that never swelled.
"This study shows that not all parts of the brain respond equally to anti-amyloid therapy," Masdeu explained. "For the first time, results show that the brain regions that swell during treatment have a greater decrease in the amyloid signal on Positron emission tomography (PET) Scan, possibly because more amyloid is removed or because amyloid is hidden on PET."
The findings suggest that ARIA-E (search) may serve as a geographic marker indicating where treatment is most actively targeting the disease. In 80% of patients studied, brain regions that experienced swelling showed more substantial clearing of amyloid plaques, challenging the traditional view of this side effect as purely problematic.
Mechanism Behind the Phenomenon
The researchers propose that the swelling occurs because anti-amyloid drugs increase local blood vessel permeability, allowing higher concentrations of medication to reach and dissolve amyloid clumps. This vascular permeability leads to plasma leakage from blood into brain tissue, resulting in the characteristic swelling visible on MRI scans.
The inflammation may also reflect an aggressive immune response, with microglia - the brain's immune cells - actively "gobbling up" amyloid in those specific regions. All participants in the study were APOE ε4 (search) carriers, a genetic variant that increases both Alzheimer's risk and susceptibility to ARIA side effects.
Clinical Implications for Treatment Management
Currently, when ARIA-E (search) appears, clinicians typically slow or briefly pause treatment while monitoring patients closely. In most cases, the swelling recedes and disappears, allowing treatment to resume. These new findings offer a more nuanced interpretation of this side effect, suggesting doctors and families should balance safety concerns with the possibility that swelling may coincide with stronger local treatment response.
"That reframes ARIA-E (search) from being only a side effect to a possible sign of strong local treatment activity," Masdeu noted.
Expanding Research Scope
With approximately 6.9 million Americans currently living with Alzheimer's - a number projected to double to 14 million by 2060 according to the Centers for Disease Control and Prevention - understanding how to optimize these breakthrough treatments is crucial.
The investigators are expanding their patient sample and collaborating with other institutions, including the Longitudinal Early Onset Alzheimer's Disease Study (LEADS) consortium, to validate results in larger, more diverse patient populations.
The study was funded by the Cho, Farish Graham, Harrison and Nantz Funds from the Houston Methodist Foundation, with additional support from the National Institutes of Health through the LEADS Consortium. Other collaborators included Quentin Finn and Belen Pascual from Houston Methodist and Paul Schulz from UTHealth Houston.